Skip to main content
QURE logo

QURE · uniQure N.V. · Webcasts, Transcripts & Audio

Track QURE — free
$20.23 -0.07 (-0.34%) Play latest call Q3 2026 earnings call transcript
Market Cap
$1.42B
Shares
70.14M
Volume · Nov 19 1.16M Avg daily vol (3M) 2.22M

uniQure N.V. Webcasts

Earnings calls, investor updates, investor days and conferences for uniQure N.V. (QURE), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Conference
Investor event
2026-11-11
uniQure N.V. (QURE) November 11, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-10
uniQure N.V. (QURE) November 10, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-11-04
uniQure N.V. (QURE) Q3 2026 Earnings Call Transcript
Confident tone Confirmatory study execution AMT-130 clinical efficacy Regulatory progress
Revenue
$5.20M
▲ 40.4% YoY
Diluted EPS
$-0.88
Gross margin
95.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2026-07-29
uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript
Confident tone AMT-130 Huntington's disease regulatory progress AMT-130 long-term clinical data FDA confirmatory trial design
Revenue
$5.84M
▲ 11% YoY
Diluted EPS
$-1.22
Gross margin
94.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-05-19
uniQure N.V. (QURE) May 19, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-05
uniQure N.V. (QURE) Q1 2026 Earnings Call Transcript
Balanced tone AMT-130 in Huntington's disease UK MHRA submission UK commercial readiness and access
Revenue
$3.56M
▲ 127.3% YoY
Diluted EPS
$-0.85
Gross margin
93.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-02
uniQure N.V. (QURE) Q4 2025 Earnings Call Transcript
Cautious tone FDA feedback on regulatory path for AMT-130 External comparator from natural history data Phase III sham-controlled study requirement
Revenue
$5.57M*
▲ 6.6% YoY
Gross margin
92.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-10
uniQure N.V. (QURE) Q3 2025 Earnings Call Transcript
Cautious tone FDA pre-BLA feedback and regulatory uncertainty AMT-130 Huntington's disease pivotal data AMT-162 SOD1 ALS program safety event
Revenue
$3.70M
▲ 61.8% YoY
Diluted EPS
$-1.38
Gross margin
89.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-29
uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript
Confident tone AMT-130 pivotal data and regulatory progress Huntington's disease competitive positioning BLA readiness and manufacturing (PPQ/CMC)
Revenue
$5.26M
▼ 52.7% YoY
Diluted EPS
$-0.69
Gross margin
87.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-06-02
uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript
Confident tone AMT-130 Huntington's program and BLA pathway Regulatory designations and FDA interactions Pipeline expansion across other gene therapy programs
Revenue
$1.57M
▼ 81.5% YoY
Diluted EPS
$-0.82
Gross margin
87.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
uniQure N.V. (QURE) Q2 2022 Earnings Call
Revenue
$497,000
▼ 99.9% YoY
Diluted EPS
$-0.84
▼ 109.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-31
uniQure N.V. (QURE) Q2 2020 Earnings Call
Revenue
$1.53M
▼ 38% YoY
Diluted EPS
$-0.96
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–12 of 12 webcasts
Key facts CIK 1590560 CUSIP N90064101 13F (30d) 268 filings 232 filers Visit website Investor relations